

Per Soelberg Srensen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/3744973/per-soelberg-sorensen-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

329
papers

25,862
citations

70
h-index

154
g-index

347
ext. papers

30,808
ext. citations

7.3
avg, IF

6.74
L-index

#	Paper	IF	Citations
329	Fitbeat: COVID-19 estimation based on wristband heart rate using a contrastive convolutional auto-encoder. <i>Pattern Recognition</i> , 2022 , 123, 108403	7.7	2
328	The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021.. <i>Multiple Sclerosis Journal</i> , 2022 , 13524585211069068	5	1
327	Population Pharmacokinetic-B \square Cell Modeling for Ofatumumab in Patients with Relapsing Multiple Sclerosis.. <i>CNS Drugs</i> , 2022 , 36, 283	6.7	0
326	Exposure to passive smoking during adolescence is associated with an increased risk of developing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 188-197	5	4
325	Expert opinion on COVID-19 vaccination and the use of cladribine tablets in clinical practice.. <i>Therapeutic Advances in Neurological Disorders</i> , 2021 , 14, 17562864211058298	6.6	1
324	Safety, tolerability, and activity of mesenchymal stem cells versus placebo in multiple sclerosis (MESEMS): a phase 2, randomised, double-blind crossover trial. <i>Lancet Neurology</i> , 2021 , 20, 917-929 ^{24.1}	24.1	9
323	Treatment Switching and Discontinuation Over 20 Years in the Big Multiple Sclerosis Data Network. <i>Frontiers in Neurology</i> , 2021 , 12, 647811	4.1	3
322	Early treatment delays long-term disability accrual in RRMS: Results from the BMSD network. <i>Multiple Sclerosis Journal</i> , 2021 , 27, 1543-1555	5	10
321	Age and sex as determinants of treatment decisions in patients with relapsing-remitting MS. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 50, 102813	4	2
320	Effect of lateral therapy switches to oral moderate-efficacy drugs in multiple sclerosis: a nationwide cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021 , 92, 556-562	5.5	4
319	The effectiveness of natalizumab vs fingolimod-A comparison of international registry studies. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103012	4	3
318	Dimethyl Fumarate Treatment in Patients With Primary Progressive Multiple Sclerosis: A Randomized, Controlled Trial. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021 , 8,	9.1	2
317	Relapses add to permanent disability in relapsing multiple sclerosis patients. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 53, 103029	4	1
316	Averting multiple sclerosis long-term societal and healthcare costs: The Value of Treatment (VoT) project. <i>Multiple Sclerosis and Related Disorders</i> , 2021 , 54, 103107	4	2
315	The window of opportunity for treatment of progressive multiple sclerosis. <i>Current Opinion in Neurology</i> , 2020 , 33, 262-270	7.1	14
314	Aggressive multiple sclerosis (2): Treatment. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520924595	5	6
313	Aggressive multiple sclerosis (1): Towards a definition of the phenotype. <i>Multiple Sclerosis Journal</i> , 2020 , 1352458520925369	5	14

312	Expert opinion on the use of cladribine tablets in clinical practice. <i>Therapeutic Advances in Neurological Disorders</i> , 2020 , 13, 1756286420935019	6.6	10
311	Initial high-efficacy disease-modifying therapy in multiple sclerosis: A nationwide cohort study. <i>Neurology</i> , 2020 , 95, e1041-e1051	6.5	28
310	Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. <i>Neurological Sciences</i> , 2020 , 41, 1647-1650	3.5	31
309	Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 40, 101956	4	6
308	Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis. <i>CNS Drugs</i> , 2020 , 34, 269-280	6.7	25
307	Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing-Remitting Multiple Sclerosis Patients? A Narrative Review. <i>Neurology and Therapy</i> , 2020 , 9, 55-66	4.6	9
306	Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19. <i>Journal of Medical Internet Research</i> , 2020 , 22, e19992	7.6	70
305	Clinical characteristics and use of disease modifying therapy in the nationwide Danish cohort of paediatric onset multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020 , 37, 101431	4	3
304	Clinically stable disease is associated with a lower risk of both income loss and disability pension for patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 67-74	5.5	8
303	The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history. <i>Brain</i> , 2020 , 143, 2637-2652	11.2	22
302	Comorbidity in Multiple Sclerosis. <i>Frontiers in Neurology</i> , 2020 , 11, 851	4.1	35
301	Predictors of treatment outcome in patients with paediatric onset multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020 , 26, 964-975	5	4
300	Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility. <i>Science</i> , 2019 , 365,	33.3	309
299	Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 29, 168-174	4	54
298	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , 2019 , 18, 185-197	24.1	74
297	MEsenchymal StEm cells for Multiple Sclerosis (MESEMS): a randomized, double blind, cross-over phase I/II clinical trial with autologous mesenchymal stem cells for the therapy of multiple sclerosis. <i>Trials</i> , 2019 , 20, 263	2.8	41
296	Worsening of disability caused by relapses in multiple sclerosis: A different approach. <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 32, 1-8	4	20
295	Comparative effectiveness of teriflunomide and dimethyl fumarate: A nationwide cohort study. <i>Neurology</i> , 2019 , 92, e1811-e1820	6.5	21

294	Pulsed immune reconstitution therapy in multiple sclerosis. <i>Therapeutic Advances in Neurological Disorders</i> , 2019 , 12, 1756286419836913	6.6	34
293	Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1298-1305	5	17
292	Prognostic value of cerebrospinal fluid neurofilament light chain and chitinase-3-like-1 in newly diagnosed patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 1444-1451	5	25
291	Effectiveness of glatiramer acetate in neutralizing antibody-positive patients previously treated with interferon- β . <i>Multiple Sclerosis and Related Disorders</i> , 2019 , 39, 101894	4	1
290	The changing course of multiple sclerosis: rising incidence, change in geographic distribution, disease course, and prognosis. <i>Current Opinion in Neurology</i> , 2019 , 32, 320-326	7.1	30
289	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study. <i>Journal of Neuroimmunology</i> , 2019 , 326, 19-27	3.5	9
288	The Multiple Sclerosis Care Unit. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 627-636	5	37
287	Treatment escalation leads to fewer relapses compared with switching to another moderately effective therapy. <i>Journal of Neurology</i> , 2019 , 266, 306-315	5.5	9
286	Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2019 , 25, 819-827	5	31
285	Progressive multiple sclerosis, cognitive function, and quality of life. <i>Brain and Behavior</i> , 2018 , 8, e008753.4	5.4	26
284	Long-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing-remitting multiple sclerosis: the CLARITY Extension study. <i>Therapeutic Advances in Neurological Disorders</i> , 2018 , 11, 1756285617753365	6.6	38
283	ECTRIMS/EAN Guideline on the pharmacological treatment of people with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 96-120	5	286
282	Disability in progressive MS is associated with T2 lesion changes. <i>Multiple Sclerosis and Related Disorders</i> , 2018 , 20, 73-77	4	4
281	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , 2018 , 17, 162-173	24.1	2419
280	Environmental modifiable risk factors for multiple sclerosis: Report from the 2016 ECTRIMS focused workshop. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 590-603	5	58
279	Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study. <i>Multiple Sclerosis Journal</i> , 2018 , 24, 1594-1604	5	140
278	Low-Frequency and Rare-Coding Variation Contributes to Multiple Sclerosis Risk. <i>Cell</i> , 2018 , 175, 1679-1687.e72	6.7	72
277	039 Rates of lymphopenia in years 1-4 in patients with relapsing multiple sclerosis treated annually with cladribine tablets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018 , 89, A16.2-A16	5.5	1

276	Early safety and efficacy of fingolimod treatment in Denmark. <i>Acta Neurologica Scandinavica</i> , 2017 , 135, 129-133	3.8	12
275	A comparison of multiple sclerosis clinical disease activity between patients treated with natalizumab and fingolimod. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 234-241	5	33
274	Spinal cord atrophy in anterior-posterior direction reflects impairment in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2017 , 136, 330-337	3.8	6
273	Chronic comorbidity in multiple sclerosis is associated with lower incomes and dissolved intimate relationships. <i>European Journal of Neurology</i> , 2017 , 24, 825-834	6	15
272	Monoclonal Antibodies for Relapsing Multiple Sclerosis: A Review of Recently Marketed and Late-Stage Agents. <i>CNS Drugs</i> , 2017 , 31, 357-371	6.7	10
271	Defining active progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1727-1735	5	22
270	Comorbidity in multiple sclerosis is associated with diagnostic delays and increased mortality. <i>Neurology</i> , 2017 , 89, 1668-1675	6.5	35
269	Employment, disability pension and income for children with parental multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 1148-1156	5	7
268	High-dose erythropoietin in patients with progressive multiple sclerosis: A randomized, placebo-controlled, phase 2 trial. <i>Multiple Sclerosis Journal</i> , 2017 , 23, 675-685	5	30
267	Safety concerns and risk management of multiple sclerosis therapies. <i>Acta Neurologica Scandinavica</i> , 2017 , 136, 168-186	3.8	47
266	Evolving concepts in the treatment of relapsing multiple sclerosis. <i>Lancet, The</i> , 2017 , 389, 1347-1356	40	185
265	Cell-based therapeutic strategies for multiple sclerosis. <i>Brain</i> , 2017 , 140, 2776-2796	11.2	102
264	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results. <i>PLoS ONE</i> , 2017 , 12, e0170395	3.7	27
263	Laquinimod Safety Profile: Pooled Analyses from the ALLEGRO and BRAVO Trials. <i>International Journal of MS Care</i> , 2017 , 19, 16-24	2.3	13
262	Association between age at onset of multiple sclerosis and vitamin D level-related factors. <i>Neurology</i> , 2016 , 86, 88-93	6.5	16
261	Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 926-34	5	19
260	Haematopoietic stem cell transplants should be a second-line therapy for highly active MS - NO. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1260-3	5	3
259	Vitamin D supplementation reduces relapse rate in relapsing-remitting multiple sclerosis patients treated with natalizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 10, 169-173	4	48

258	Inverse comorbidity in multiple sclerosis: Findings in a complete nationwide cohort. <i>Multiple Sclerosis and Related Disorders</i> , 2016 , 10, 181-186	4	12
257	NR1H3 p.Arg415Gln Is Not Associated to Multiple Sclerosis Risk. <i>Neuron</i> , 2016 , 92, 333-335	13.9	19
256	Recovery from an acute relapse is associated with changes in motor resting-state connectivity in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016 , 87, 912-4	5.5	6
255	Development and validation of cell-based luciferase reporter gene assays for measuring neutralizing anti-drug antibodies against interferon beta. <i>Journal of Immunological Methods</i> , 2016 , 430, 1-9	2.5	10
254	Multiple sclerosis. Generic glatiramer acetate--a step toward cheaper MS drugs?. <i>Nature Reviews Neurology</i> , 2016 , 12, 5-6	15	5
253	Ozanimod: a better or just another S1P receptor modulator?. <i>Lancet Neurology, The</i> , 2016 , 15, 345-7	24.1	8
252	Cytokine profiles show heterogeneity of interferon- β response in multiple sclerosis patients. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016 , 3, e202	9.1	26
251	The potential role for ocrelizumab in the treatment of multiple sclerosis: current evidence and future prospects. <i>Therapeutic Advances in Neurological Disorders</i> , 2016 , 9, 44-52	6.6	77
250	The Danish Multiple Sclerosis Treatment Register. <i>Clinical Epidemiology</i> , 2016 , 8, 549-552	5.9	27
249	Occurrence of Anti-Drug Antibodies against Interferon-Beta and Natalizumab in Multiple Sclerosis: A Collaborative Cohort Analysis. <i>PLoS ONE</i> , 2016 , 11, e0162752	3.7	30
248	Minocycline added to subcutaneous interferon β 1a in multiple sclerosis: randomized RECYCLINE study. <i>European Journal of Neurology</i> , 2016 , 23, 861-70	6	24
247	Pharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 1386-1396	5	83
246	Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine. <i>Multiple Sclerosis Journal</i> , 2016 , 22, 944-54	5	19
245	Educational achievements of children of parents with multiple sclerosis: A nationwide register-based cohort study. <i>Journal of Neurology</i> , 2016 , 263, 2229-2237	5.5	6
244	Vascular comorbidities in multiple sclerosis: a nationwide study from Denmark. <i>Journal of Neurology</i> , 2016 , 263, 2484-2493	5.5	32
243	Trichuris suis ova therapy in relapsing multiple sclerosis is safe but without signals of beneficial effect. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1723-9	5	47
242	Therapeutic interference with leukocyte recirculation in multiple sclerosis. <i>European Journal of Neurology</i> , 2015 , 22, 434-42	6	7
241	Factors influencing success of clinical genome sequencing across a broad spectrum of disorders. <i>Nature Genetics</i> , 2015 , 47, 717-726	36.3	244

240	The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: a systematic review. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 332-41	5	30
239	A systematic review of the incidence and prevalence of autoimmune disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 282-93	5	91
238	A systematic review of the incidence and prevalence of cancer in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 294-304	5	57
237	A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 342-9	5	76
236	A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 318-31	5	92
235	Endogenous interferon- β -inducible gene expression and interferon- β treatment are associated with reduced T cell responses to myelin basic protein in multiple sclerosis. <i>PLoS ONE</i> , 2015 , 10, e0118830	3.7	14
234	Genetic and environmental determinants of 25-hydroxyvitamin D levels in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1414-22	5	17
233	A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: overview. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 263-81	5	203
232	The incidence and prevalence of psychiatric disorders in multiple sclerosis: a systematic review. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 305-17	5	286
231	Short-term, high-dose glucocorticoid treatment does not contribute to reduced bone mineral density in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2015 , 21, 1557-65	5	14
230	FoxA1 directs the lineage and immunosuppressive properties of a novel regulatory T cell population in EAE and MS. <i>Nature Medicine</i> , 2014 , 20, 272-82	50.5	103
229	A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. <i>Journal of Neurology</i> , 2014 , 261, 773-83	5.5	136
228	Recurrence or rebound of clinical relapses after discontinuation of natalizumab therapy in highly active MS patients. <i>Journal of Neurology</i> , 2014 , 261, 1170-7	5.5	107
227	Immunological effects of methylprednisolone pulse treatment in progressive multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2014 , 276, 195-201	3.5	6
226	Physical and social environment and the risk of multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2014 , 3, 600-6	4	16
225	Defining the clinical course of multiple sclerosis: the 2013 revisions. <i>Neurology</i> , 2014 , 83, 278-86	6.5	1632
224	Multiple sclerosis impairs regional functional connectivity in the cerebellum. <i>NeuroImage: Clinical</i> , 2014 , 4, 130-8	5.3	32
223	Secondary progressive and relapsing remitting multiple sclerosis leads to motor-related decreased anatomical connectivity. <i>PLoS ONE</i> , 2014 , 9, e95540	3.7	15

222	Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 577-87	5	35
221	Cortical N-acetyl aspartate is a predictor of long-term clinical disability in multiple sclerosis. <i>Neurological Research</i> , 2014 , 36, 701-8	2.7	6
220	Prediction of response to interferon therapy in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2014 , 130, 268-75	3.8	20
219	The chemokine receptor CCR5 B2 allele in natalizumab-treated multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2014 , 129, 27-31	3.8	6
218	Gender effects on treatment response to interferon-beta in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2014 , 130, 374-9	3.8	11
217	New management algorithms in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2014 , 27, 246-59	7.1	75
216	Gender and autoimmune comorbidity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014 , 20, 1244-51	5	16
215	Effects of fingolimod in relapsing-remitting multiple sclerosis. <i>Lancet Neurology</i> , 2014 , 13, 526-7	24.1	6
214	Dendritic cell, monocyte and T cell activation and response to glatiramer acetate in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 179-87	5	22
213	MRI outcomes with cladribine tablets for multiple sclerosis in the CLARITY study. <i>Journal of Neurology</i> , 2013 , 260, 1136-46	5.5	33
212	Differential microRNA expression in blood in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1849-57	5.7	86
211	Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. <i>Nature Genetics</i> , 2013 , 45, 1353-60	36.3	934
210	Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1841-8	5	25
209	Preserved in vivo response to interferon-alpha in multiple sclerosis patients with neutralising antibodies against interferon-beta (REPAIR study). <i>Multiple Sclerosis and Related Disorders</i> , 2013 , 2, 141-6	4	4
208	Resting-state connectivity of pre-motor cortex reflects disability in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2013 , 128, 328-35	3.8	26
207	Disease-modifying treatments for relapsing-remitting multiple sclerosis 2013 , 64-87		
206	Expanded functional coupling of subcortical nuclei with the motor resting-state network in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 559-66	5	35
205	Clinically silent PML and prolonged immune reconstitution inflammatory syndrome in a patient with multiple sclerosis treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1226-9	5	17

204	Reproduction and the risk of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1604-9	5	51
203	Anti-JC virus antibody prevalence in a multinational multiple sclerosis cohort. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 1533-8	5	79
202	CSF inflammation and axonal damage are increased and correlate in progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013 , 19, 877-84	5	62
201	Prolonged-release fampridine improves walking in a proportion of patients with multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2013 , 13, 1309-17	4.3	4
200	Systemic inflammation in progressive multiple sclerosis involves follicular T-helper, Th17- and activated B-cells and correlates with progression. <i>PLoS ONE</i> , 2013 , 8, e57820	3.7	157
199	Cognitive deficits in multiple sclerosis: correlations with T2 changes in normal appearing brain tissue. <i>Acta Neurologica Scandinavica</i> , 2012 , 125, 338-44	3.8	16
198	Chronic cerebrospinal venous insufficiency and venous stenoses in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2012 , 126, 421-7	3.8	29
197	Cladribine tablets for relapsing-remitting multiple sclerosis: Efficacy across patient subgroups from the phase III CLARITY study. <i>Multiple Sclerosis and Related Disorders</i> , 2012 , 1, 49-54	4	21
196	Correlation between anti-interferon-β binding and neutralizing antibodies in interferon-β treated multiple sclerosis patients. <i>European Journal of Neurology</i> , 2012 , 19, 1311-7	6	13
195	FOXP3, CBLB and ITCH gene expression and cytotoxic T lymphocyte antigen 4 expression on CD4(+) CD25(high) T cells in multiple sclerosis. <i>Clinical and Experimental Immunology</i> , 2012 , 170, 149-55	6.2	26
194	Association between DPP6 polymorphism and the risk of progressive multiple sclerosis in Northern and Southern Europeans. <i>Neuroscience Letters</i> , 2012 , 530, 155-60	3.3	11
193	Risk stratification for progressive multifocal leukoencephalopathy in patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 143-52	5	186
192	Cellular sources of dysregulated cytokines in relapsing-remitting multiple sclerosis. <i>Journal of Neuroinflammation</i> , 2012 , 9, 215	10.1	58
191	Reduction in healthcare and societal resource utilization associated with cladribine tablets in patients with relapsing-remitting multiple sclerosis: analysis of economic data from the CLARITY Study. <i>Clinical Drug Investigation</i> , 2012 , 32, 15-27	3.2	9
190	Segmenting Multiple Sclerosis Lesions Using a Spatially Constrained K-Nearest Neighbour Approach. <i>Lecture Notes in Computer Science</i> , 2012 , 156-163	0.9	1
189	Endogenous and recombinant type I interferons and disease activity in multiple sclerosis. <i>PLoS ONE</i> , 2012 , 7, e35927	3.7	11
188	Effect of natalizumab on circulating CD4+ T-cells in multiple sclerosis. <i>PLoS ONE</i> , 2012 , 7, e47578	3.7	42
187	Prediction of antibody persistency from antibody titres to natalizumab. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1493-9	5	18

186	Deaths and disability from natalizumab are no longer tolerable: No - (they can be avoided). <i>Multiple Sclerosis Journal</i> , 2012 , 18, 1070-2	5	1
185	Glatiramer acetate antibodies, gene expression and disease activity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012 , 18, 305-13	5	19
184	Cerebral metabolism, magnetic resonance spectroscopy and cognitive dysfunction in early multiple sclerosis: an exploratory study. <i>Neurological Research</i> , 2012 , 34, 52-8	2.7	11
183	Why does the north-south gradient of incidence of multiple sclerosis seem to have disappeared on the northern hemisphere?. <i>Journal of the Neurological Sciences</i> , 2011 , 311, 58-63	3.2	55
182	Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2011 , 311 Suppl 1, S29-34	3.2	14
181	Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRibine Tablets treating multiple sclerosis orally) study. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 578-93	5	88
180	Cladribine in the treatment of multiple sclerosis. <i>Clinical Investigation</i> , 2011 , 1, 317-326		3
179	Disease protection and interleukin-10 induction by endogenous interferon- β in multiple sclerosis?. <i>European Journal of Neurology</i> , 2011 , 18, 266-272	6	35
178	Alterations in KLRB1 gene expression and a Scandinavian multiple sclerosis association study of the KLRB1 SNP rs4763655. <i>European Journal of Human Genetics</i> , 2011 , 19, 1100-3	5.3	6
177	Sustained disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with cladribine tablets in the CLARITY study: a post-hoc and subgroup analysis. <i>Lancet Neurology, The</i> , 2011 , 10, 329-37	24.1	156
176	Simvastatin as add-on therapy to interferon β 1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. <i>Lancet Neurology, The</i> , 2011 , 10, 691-701	24.1	92
175	Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. <i>Lancet Neurology, The</i> , 2011 , 10, 745-58	24.1	212
174	Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. <i>Nature</i> , 2011 , 476, 214-9	50.4	1948
173	Occurrence of antibodies against natalizumab in relapsing multiple sclerosis patients treated with natalizumab. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 1074-8	5	42
172	Neutralizing antibodies against interferon- β do not predispose antibodies against natalizumab. <i>Neurology</i> , 2011 , 76, 759-60	6.5	12
171	Osteopontin concentrations are increased in cerebrospinal fluid during attacks of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011 , 17, 32-42	5	54
170	Principles of a new treatment algorithm in multiple sclerosis. <i>Expert Review of Neurotherapeutics</i> , 2011 , 11, 351-62	4.3	20
169	Genetic variants of CC chemokine genes in experimental autoimmune encephalomyelitis, multiple sclerosis and rheumatoid arthritis. <i>Genes and Immunity</i> , 2010 , 11, 142-54	4.4	19

168	Demyelination versus remyelination in progressive multiple sclerosis. <i>Brain</i> , 2010 , 133, 2983-98	11.2	200
167	A placebo-controlled trial of oral cladribine for relapsing multiple sclerosis. <i>New England Journal of Medicine</i> , 2010 , 362, 416-26	59.2	591
166	Polymorphisms of innate pattern recognition receptors, response to interferon-beta and development of neutralizing antibodies in multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2010 , 16, 942-9	5	28
165	The changing demographic pattern of multiple sclerosis epidemiology. <i>Lancet Neurology</i> , 2010 , 9, 520-32	24.1	737
164	Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. <i>Lancet Neurology</i> , 2010 , 9, 740-50	24.1	164
163	Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial. <i>Lancet Neurology</i> , 2010 , 9, 672-80	24.1	62
162	EFNS guidelines on diagnosis and management of neuromyelitis optica. <i>European Journal of Neurology</i> , 2010 , 17, 1019-32	6	292
161	Effects of infectious mononucleosis and HLA-DRB1*15 in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 431-6	5	74
160	Treatment with azathioprine and cyclic methylprednisolone has little or no effect on bioactivity in anti-interferon beta antibody-positive patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 323-8	5	18
159	The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 601-5	5	23
158	The relation between inflammation and neurodegeneration in multiple sclerosis brains. <i>Brain</i> , 2009 , 132, 1175-89	11.2	944
157	Multiple sclerosis and polymorphisms of innate pattern recognition receptors TLR1-10, NOD1-2, DDX58, and IFIH1. <i>Journal of Neuroimmunology</i> , 2009 , 212, 125-31	3.5	51
156	NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial. <i>Lancet Neurology</i> , 2009 , 8, 519-29	24.1	85
155	Autoantibodies to myelin basic protein (MBP) in healthy individuals and in patients with multiple sclerosis: a role in regulating cytokine responses to MBP. <i>Immunology</i> , 2009 , 128, e451-61	7.8	46
154	Methylprednisolone does not restore biological response in multiple sclerosis patients with neutralizing antibodies against interferon- β . <i>European Journal of Neurology</i> , 2009 , 16, 43-7	6	20
153	Efficacy of natalizumab in multiple sclerosis patients with high disease activity: a Danish nationwide study. <i>European Journal of Neurology</i> , 2009 , 16, 420-3	6	68
152	How effective is natalizumab as second-line treatment for multiple sclerosis in daily clinical praxis?. <i>European Journal of Neurology</i> , 2009 , 16, 287-8	6	1
151	Identification of new sensitive biomarkers for the in vivo response to interferon-beta treatment in multiple sclerosis using DNA-array evaluation. <i>European Journal of Neurology</i> , 2009 , 16, 1291-8	6	46

150	Safety and immunogenicity of a new formulation of interferon beta-1a (Rebif New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results. <i>Multiple Sclerosis Journal</i> , 2009 , 15, 219-28	5	63
149	EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: EFNS task force on the use of intravenous immunoglobulin in treatment of neurological diseases. <i>European Journal of Neurology</i> , 2008 , 15, 893-908	6	211
148	The effect of beta-interferon therapy on myelin basic protein-elicited CD4+ T cell proliferation and cytokine production in multiple sclerosis. <i>Clinical Immunology</i> , 2008 , 129, 80-9	9	12
147	REGARD: what can we learn from randomised, open-label, head-to-head studies?. <i>Lancet Neurology, The</i> , 2008 , 7, 864-6	24.1	4
146	The SH2D2A gene and susceptibility to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2008 , 197, 152-83.5	13	
145	Intravenous polyclonal human immunoglobulins in multiple sclerosis. <i>Neurodegenerative Diseases</i> , 2008 , 5, 8-15	2.3	13
144	Oral fumarate for relapsing-remitting multiple sclerosis. <i>Lancet, The</i> , 2008 , 372, 1447-8	40	6
143	Gene expression analysis of interferon-beta treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 615-21	5	32
142	Neutralizing antibodies against interferon-Beta. <i>Therapeutic Advances in Neurological Disorders</i> , 2008 , 1, 125-41	6.6	25
141	Can we spot the IFNbeta nonresponders?. <i>Neurology</i> , 2008 , 71, 1936-7	6.5	2
140	Is the treatment effect of IFN-beta restored after the disappearance of neutralizing antibodies?. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 837-42	5	20
139	Fatal neurogenic pulmonary edema in a patient with progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 711-5	5	17
138	Increased IL-10 mRNA and IL-23 mRNA expression in multiple sclerosis: interferon-beta treatment increases IL-10 mRNA expression while reducing IL-23 mRNA expression. <i>Multiple Sclerosis Journal</i> , 2008 , 14, 622-30	5	59
137	Re: Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. <i>Journal of International Medical Research</i> , 2008 , 36, 204-8; author reply 208-10	1.4	2
136	The gap between effect of drugs and effectiveness of treatments. <i>Journal of the Neurological Sciences</i> , 2007 , 259, 128-32	3.2	4
135	Widespread demyelination in the cerebellar cortex in multiple sclerosis. <i>Brain Pathology</i> , 2007 , 17, 38-446		254
134	Using measurements of neutralizing antibodies: the challenge of IFN-beta therapy. <i>European Journal of Neurology</i> , 2007 , 14, 850-9	6	38
133	Resource allocation to brain research in Europe. <i>European Journal of Neurology</i> , 2007 , 14, 597	6	

132	IVIG enters the central nervous system during treatment of experimental autoimmune encephalomyelitis and is localised to inflammatory lesions. <i>Experimental Brain Research</i> , 2007 , 178, 462-9 ³	3.3	17
131	Neutralising antibodies to interferon beta in multiple sclerosis : expert panel report. <i>Journal of Neurology</i> , 2007 , 254, 827-37	5.5	45
130	Health-related quality of life in secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 386-92	5	33
129	Multiple sclerosis after infectious mononucleosis. <i>Archives of Neurology</i> , 2007 , 64, 72-5		141
128	Are ex vivo neutralising antibodies against IFN-beta always detrimental to therapeutic efficacy in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 616-21	5	29
127	Re: Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. <i>Neurology</i> , 2007 , 69, 1552; author reply 1553	6.5	6
126	Immunogenicity and tolerability of an investigational formulation of interferon-beta1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. <i>Clinical Therapeutics</i> , 2007 , 29, 1128-45	3.5	34
125	A follow-up study of Nordic multiple sclerosis candidate gene regions. <i>Multiple Sclerosis Journal</i> , 2007 , 13, 584-9	5	
124	CD4(+) memory T cells with high CD26 surface expression are enriched for Th1 markers and correlate with clinical severity of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2006 , 181, 157-64	3.5	48
123	Remyelination is extensive in a subset of multiple sclerosis patients. <i>Brain</i> , 2006 , 129, 3165-72	11.2	558
122	Correlation of global N-acetyl aspartate with cognitive impairment in multiple sclerosis. <i>Archives of Neurology</i> , 2006 , 63, 533-6		53
121	Neutralizing antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. <i>Neurology</i> , 2006 , 67, 1681-3	6.5	57
120	The efficacy of multidisciplinary rehabilitation in stable multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 235-42	5	52
119	Measuring and evaluating interferon beta-induced antibodies in patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 39-46	5	30
118	Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 247-52	5	46
117	Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 253-64	5	26
116	The six spot step test: a new measurement for walking ability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2006 , 12, 495-500	5	77
115	Cognitive impairment in newly diagnosed multiple sclerosis patients: a 4-year follow-up study. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 77-85	3.2	67

114	The relationship between MRI and PET changes and cognitive disturbances in MS. <i>Journal of the Neurological Sciences</i> , 2006 , 245, 99-102	3.2	14
113	A prospective PET study of patients with glioblastoma multiforme. <i>Acta Neurologica Scandinavica</i> , 2006 , 113, 412-8	3.8	2
112	Dynamic T-lymphocyte chemokine receptor expression induced by interferon-beta therapy in multiple sclerosis. <i>Scandinavian Journal of Immunology</i> , 2006 , 64, 155-63	3.4	25
111	Neutralising antibodies to interferon-β measurement, clinical relevance, and management. <i>Journal of Neurology</i> , 2006 , 253, vi16-vi22	5.5	0
110	Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. <i>Journal of the Neurological Sciences</i> , 2005 , 233, 61-5	3.2	39
109	EFNS guideline on treatment of multiple sclerosis relapses: report of an EFNS task force on treatment of multiple sclerosis relapses. <i>European Journal of Neurology</i> , 2005 , 12, 939-46	6	106
108	Guidelines on use of anti-IFN-beta antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN-beta antibodies in multiple sclerosis. <i>European Journal of Neurology</i> , 2005 , 12, 817-27	6	202
107	Multiple sclerosis: pathophysiology revisited. <i>Lancet Neurology</i> , 2005 , 4, 9-10	24.1	12
106	Multi-slice echo-planar spectroscopic MR imaging provides both global and local metabolite measures in multiple sclerosis. <i>Magnetic Resonance in Medicine</i> , 2005 , 53, 750-9	4.4	22
105	Appearance and disappearance of neutralizing antibodies during interferon-beta therapy. <i>Neurology</i> , 2005 , 65, 33-9	6.5	161
104	Therapeutic considerations for disease progression in multiple sclerosis: evidence, experience, and future expectations. <i>Archives of Neurology</i> , 2005 , 62, 1519-30		22
103	CD26 + CD4 + T cell counts and attack risk in interferon-treated multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 641-5	5	14
102	Intravenous immunoglobulin ameliorates experimental autoimmune encephalomyelitis and reduces neuropathological abnormalities when administered prophylactically. <i>Neurological Research</i> , 2005 , 27, 591-7	2.7	19
101	Responsiveness of the Multiple Sclerosis Impairment Scale in comparison with the Expanded Disability Status Scale. <i>Multiple Sclerosis Journal</i> , 2005 , 11, 81-4	5	24
100	MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS). <i>Multiple Sclerosis Journal</i> , 2005 , 11, 433-40	5	39
99	Concordance for disease course and age of onset in Scandinavian multiple sclerosis coaffected sib pairs. <i>Multiple Sclerosis Journal</i> , 2004 , 10, 5-8	5	23
98	IV immunoglobulins as add-on treatment to methylprednisolone for acute relapses in MS. <i>Neurology</i> , 2004 , 63, 2028-33	6.5	87
97	Genes in the HLA class I region may contribute to the HLA class II-associated genetic susceptibility to multiple sclerosis. <i>Tissue Antigens</i> , 2004 , 63, 237-47		115

96	Early-stage multiple sclerosis : what are the treatment options?. <i>Drugs</i> , 2004 , 64, 2021-9	12.1	
95	Significantly increased fractions of transformed to total alpha2-macroglobulin concentrations in plasma from patients with multiple sclerosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2004 , 1690, 203-7	6.9	17
94	Neutralising antibodies against interferon beta in multiple sclerosis. <i>Lancet, The</i> , 2004 , 363, 168-169	40	2
93	Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial. <i>Lancet, The</i> , 2004 , 364, 1149-56	40	153
92	Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. <i>Neurology</i> , 2004 , 63, S42-9	6.5	21
91	Risk factors for acute respiratory tract infections in young Greenlandic children. <i>American Journal of Epidemiology</i> , 2003 , 158, 374-84	3.8	81
90	Association between an interleukin-13 promoter polymorphism and atopy. <i>International Journal of Immunogenetics</i> , 2003 , 30, 355-9		60
89	Two genome-wide linkage disequilibrium screens in Scandinavian multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2003 , 143, 101-6	3.5	14
88	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon beta1a. <i>Annals of Neurology</i> , 2003 , 53, 718-24	9.4	96
87	The role of intravenous immunoglobulin in the treatment of multiple sclerosis. <i>Journal of the Neurological Sciences</i> , 2003 , 206, 123-30	3.2	26
86	Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. <i>Lancet, The</i> , 2003 , 362, 1184-91	40	315
85	Antibodies to IFN-beta: the Danish National IFN-beta Project. <i>Neurology</i> , 2003 , 61, S27-8	6.5	8
84	Population-based study of acute respiratory infections in children, Greenland. <i>Emerging Infectious Diseases</i> , 2002 , 8, 586-93	10.2	49
83	Intravenous immunoglobulin G for the treatment of relapsing-remitting multiple sclerosis: a meta-analysis. <i>European Journal of Neurology</i> , 2002 , 9, 557-63	6	98
82	A genome-wide screen for linkage in Nordic sib-pairs with multiple sclerosis. <i>Genes and Immunity</i> , 2002 , 3, 279-85	4.4	67
81	Disease severity in Danish multiple sclerosis patients evaluated by MRI and three genetic markers (HLA-DRB1*1501, CCR5 deletion mutation, apolipoprotein E). <i>Multiple Sclerosis Journal</i> , 2002 , 8, 295-8	5	49
80	Correlations of brain MRI parameters to disability in multiple sclerosis. <i>Acta Neurologica Scandinavica</i> , 2001 , 104, 24-30	3.8	24
79	The T cell regulator gene SH2D2A contributes to the genetic susceptibility of multiple sclerosis. <i>Genes and Immunity</i> , 2001 , 2, 263-8	4.4	41

78	Linkage analysis suggests a region of importance for multiple sclerosis in 3p14-13. <i>Genes and Immunity</i> , 2001 , 2, 451-4	4.4	3
77	No linkage or association of the nitric oxide synthase genes to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2001 , 119, 95-100	3.5	14
76	Acute respiratory tract infections and mannose-binding lectin insufficiency during early childhood. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 285, 1316-21	27.4	322
75	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet, The</i> , 2001 , 357, 1576-82	4.0	884
74	Immunogenicity of interferon- β in multiple sclerosis patients: Influence of preparation, dosage, dose frequency, and route of administration. <i>Annals of Neurology</i> , 2000 , 48, 706-712	9.4	192
73	A new millennium? perhaps. A new european journal of Neurology? certainly!. <i>European Journal of Neurology</i> , 2000 , 7, 1	6	1
72	Prognostic factors in metastatic spinal cord compression: a prospective study using multivariate analysis of variables influencing survival and gait function in 153 patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2000 , 46, 1163-9	4	201
71	Linkage analysis of a candidate region in Scandinavian sib pairs with multiple sclerosis reveals linkage to chromosome 17q. <i>Genes and Immunity</i> , 2000 , 1, 456-9	4.4	26
70	Correlates of heterosexual behavior among 23-87 year olds in Denmark and Sweden, 1992-1998. <i>Archives of Sexual Behavior</i> , 2000 , 29, 91-106	3.5	14
69	The Effect on MRI of Gammaglobulin Treatment in Relapsing Multiple Sclerosis. <i>Multiple Sclerosis Journal</i> , 2000 , 6, S14-S17	5	
68	Viral load of human papilloma virus 16 as a determinant for development of cervical carcinoma in situ: a nested case-control study. <i>Lancet, The</i> , 2000 , 355, 2189-93	4.0	308
67	Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. <i>Lancet, The</i> , 2000 , 355, 2194-8	4.0	269
66	Intravenous immunoglobulin treatment in neurologic disorders: yes. <i>Archives of Neurology</i> , 1999 , 56, 1025-7		4
65	Smoking and oral contraceptives as risk factors for cervical carcinoma in situ. <i>International Journal of Cancer</i> , 1999 , 81, 357-65	7.5	74
64	Radiologic features compared to clinical findings in a prospective study of 153 patients with metastatic spinal cord compression treated by radiotherapy. <i>Acta Neurochirurgica</i> , 1997 , 139, 105-11	3	17
63	Intravenous immunoglobulin G therapy: effects of acute and chronic treatment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 1996 , 1, 349-52	5	6
62	Sumatriptan has no clinically relevant effect in the treatment of episodic tension-type headache. <i>European Journal of Neurology</i> , 1996 , 3, 23-28	6	52
61	Second occurrence of symptomatic metastatic spinal cord compression and findings of multiple spinal epidural metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 1995 , 33, 595-8	4	42

60	Central motor conduction as a measure of disease progression in early multiple sclerosis. <i>European Journal of Neurology</i> , 1995 , 1, 233-41	6	2
59	Comparison of clinical neurological function and CT response during chemotherapy for initial brain metastases from small cell lung cancer. <i>Acta Neurologica Scandinavica</i> , 1994 , 89, 372-7	3.8	2
58	Tolfenamic acid versus propranolol in the prophylactic treatment of migraine. <i>Acta Neurologica Scandinavica</i> , 1994 , 89, 446-50	3.8	7
57	Cerebrospinal fluid flow and production in patients with normal pressure hydrocephalus studied by MRI. <i>Neuroradiology</i> , 1994 , 36, 210-5	3.2	92
56	Assessment of CSF dynamics and venous flow in the superior sagittal sinus by MRI in idiopathic intracranial hypertension: a preliminary study. <i>Neuroradiology</i> , 1994 , 36, 350-4	3.2	44
55	Symptoms and signs in metastatic spinal cord compression: a study of progression from first symptom until diagnosis in 153 patients. <i>European Journal of Cancer</i> , 1994 , 30A, 396-8	7.5	184
54	Comparison of myelography combined with postmyelographic spinal CT and MRI in suspected metastatic disease of the spinal canal. <i>Journal of Neuro-Oncology</i> , 1992 , 13, 231-7	4.8	22
53	Flunarizine versus metoprolol in migraine prophylaxis: a double-blind, randomized parallel group study of efficacy and tolerability. <i>Headache</i> , 1991 , 31, 650-7	4.2	52
52	Intracranial pressure and cerebrospinal fluid outflow conductance in healthy subjects. <i>Journal of Neurosurgery</i> , 1991 , 74, 597-600	3.2	126
51	Carotid artery disease and low cerebral perfusion pressure: symptomatology, operative risk and outcome. <i>Neurological Research</i> , 1990 , 12, 35-40	2.7	2
50	Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. <i>Acta Neurochirurgica</i> , 1990 , 107, 37-43	3	280
49	Sexual dysfunction in male and female patients with epilepsy: a study of 86 outpatients. <i>Archives of Sexual Behavior</i> , 1990 , 19, 1-14	3.5	66
48	Metastatic epidural spinal cord compression. Results of treatment and survival. <i>Cancer</i> , 1990 , 65, 1502-86.4		188
47	Long-term prognosis and quality of life after reversible cerebral ischemic attacks. <i>Acta Neurologica Scandinavica</i> , 1989 , 79, 204-13	3.8	27
46	Prophylactic Effect of Flunarizine versus Metoprolol in Migraine. <i>Cephalalgia</i> , 1989 , 9, 355-356	6.1	3
45	Clinical course and prognosis of pseudotumor cerebri. A prospective study of 24 patients. <i>Acta Neurologica Scandinavica</i> , 1988 , 77, 164-72	3.8	50
44	Do concentrations of neurotransmitters measured in lumbar cerebrospinal fluid reflect the concentrations at brain level?. <i>Acta Neurochirurgica</i> , 1988 , 91, 55-9	3	25
43	Stroke incidence and risk factors for stroke in Copenhagen, Denmark. <i>Stroke</i> , 1988 , 19, 1345-53	6.7	185

42	Danish very-low-dose aspirin after carotid endarterectomy trial. <i>Stroke</i> , 1988 , 19, 1211-5	6.7	106
41	CSF-amine metabolites in depression, dementia and in controls. <i>Acta Psychiatrica Scandinavica</i> , 1987 , 75, 619-28	6.5	33
40	Intracerebral haemorrhage after carotid endarterectomy. <i>European Journal of Vascular Surgery</i> , 1987 , 1, 51-60		64
39	Cerebral blood flow in patients with normal-pressure hydrocephalus before and after shunting. <i>Journal of Neurosurgery</i> , 1987 , 66, 379-87	3.2	75
38	Absence of hydrocephalus in spite of impaired cerebrospinal fluid absorption and severe intracranial hypertension. <i>Acta Neurochirurgica</i> , 1987 , 86, 93-7	3	29
37	Resistance to cerebrospinal fluid outflow and intracranial pressure in patients with hydrocephalus after subarachnoid haemorrhage. <i>Acta Neurochirurgica</i> , 1987 , 88, 79-86	3	47
36	Persistent disturbances of cognitive functions in patients with pseudotumor cerebri. <i>Acta Neurologica Scandinavica</i> , 1986 , 73, 264-8	3.8	28
35	A placebo-controlled, double-blind, cross-over trial of flunarizine in common migraine. <i>Cephalalgia</i> , 1986 , 6, 7-14	6.1	64
34	Studies of vasopressin in the human cerebrospinal fluid. <i>Acta Neurologica Scandinavica</i> , 1986 , 74, 81-102	3.8	34
33	Motor disturbances in normal-pressure hydrocephalus. Special reference to stance and gait. <i>Archives of Neurology</i> , 1986 , 43, 34-8		68
32	Endocrine studies in patients with pseudotumor cerebri. Estrogen levels in blood and cerebrospinal fluid. <i>Archives of Neurology</i> , 1986 , 43, 902-6		45
31	Cerebrospinal fluid bombesin and calcitonin in patients with central nervous system metastases from small-cell lung cancer. <i>Journal of Clinical Oncology</i> , 1986 , 4, 1620-7	2.2	26
30	Cardiac disease in patients with reversible cerebral ischemic events. <i>Acta Medica Scandinavica</i> , 1985 , 217, 417-21		2
29	Ophthalmologic prognosis in benign intracranial hypertension. <i>Acta Ophthalmologica</i> , 1985 , 173, 62-4	3.7	4
28	Severe headache as the only symptom of long-standing shunt dysfunction in hydrocephalic children with normal or slit ventricles revealed by computed tomography. <i>Child's Nervous System</i> , 1985 , 1, 49-52	1.7	24
27	Cerebrospinal fluid and plasma vasopressin during short-time induced intracranial hypertension. <i>Acta Neurochirurgica</i> , 1985 , 77, 46-51	3	10
26	Cerebrospinal fluid vasopressin as a marker of central nervous system metastases from small-cell bronchogenic carcinoma. <i>Journal of Clinical Oncology</i> , 1985 , 3, 48-53	2.2	15
25	Visual evoked potentials in pseudotumor cerebri. <i>Archives of Neurology</i> , 1985 , 42, 150-3		31

24	24-hour cerebrospinal fluid levels of vasopressin in hydrocephalic patients. <i>Regulatory Peptides</i> , 1985 , 10, 115-26		8
23	High cerebrospinal fluid concentration of glial fibrillary acidic protein (GFAP) in patients with normal pressure hydrocephalus. <i>Journal of the Neurological Sciences</i> , 1985 , 70, 269-74	3.2	42
22	Plasma vasopressin, cortisol, and growth hormone concentrations in relation to surgery in the suprasellar region. <i>Acta Medica Scandinavica</i> , 1984 , 216, 31-9		1
21	Prevalence of mitral valve prolapse in younger patients with cerebral ischaemic attacks. A blinded controlled study. <i>Acta Medica Scandinavica</i> , 1984 , 216, 385-91		15
20	Bone lesions in early syphilis detected by bone scintigraphy. <i>Sexually Transmitted Infections</i> , 1984 , 60, 265-8	2.8	7
19	Impermeability of the blood-cerebrospinal fluid barrier to 1-deamino-8-D-arginine-vasopressin (DDAVP) in patients with acquired, communicating hydrocephalus. <i>European Journal of Clinical Investigation</i> , 1984 , 14, 435-9	4.6	39
18	Cerebrospinal fluid vasopressin and increased intracranial pressure. <i>Annals of Neurology</i> , 1984 , 15, 435-40	4.4	37
17	Effects of long-term carbamazepine treatment on water metabolism and plasma vasopressin concentration. <i>European Journal of Clinical Pharmacology</i> , 1984 , 26, 719-22	2.8	22
16	A case of malignant lymphoma and myasthenia gravis. <i>Scandinavian Journal of Haematology</i> , 1983 , 31, 155-60		7
15	Low cerebrospinal fluid concentration of brain-specific protein D2 in patients with normal pressure hydrocephalus. <i>Journal of the Neurological Sciences</i> , 1983 , 62, 59-65	3.2	23
14	Prognostic value of in vitro measurements of platelet aggregability and fibrinolytic activity in patients with reversible cerebral ischemic attacks. <i>European Neurology</i> , 1983 , 22, 437-41	2.1	8
13	Prevalence of stroke in a district of Copenhagen the copenhagen city heart study. <i>Acta Neurologica Scandinavica</i> , 1982 , 66, 68-81	3.8	46
12	Vasopressin release during electroconvulsive therapy. <i>Psychoneuroendocrinology</i> , 1982 , 7, 303-8	5	14
11	Vasopressin in the cerebrospinal fluid of patients with normal pressure hydrocephalus and benign intracranial hypertension. <i>European Journal of Endocrinology</i> , 1982 , 100, 211-5	6.5	28
10	Long-term prognosis after transient ischemic attacks. <i>Acta Neurologica Scandinavica</i> , 1981 , 63, 156-68	3.8	34
9	The incidence and clinical presentation of neurosyphilis in Greater Copenhagen 1974 through 1978. <i>Acta Neurologica Scandinavica</i> , 1981 , 63, 237-46	3.8	14
8	Electroconvulsive therapy: a comparison of seizure duration as monitored with electroencephalograph and electromyograph. <i>Acta Psychiatrica Scandinavica</i> , 1981 , 64, 193-8	6.5	9
7	Essential tremor treated with propranolol: lack of correlation between clinical effect and plasma propranolol levels. <i>Annals of Neurology</i> , 1981 , 9, 53-7	9.4	20

- 6 Elektromyografisk monitorering ved narko-curare-elektrostimulation. *Nordic Journal of Psychiatry*, **1979**, 33, 9-14 1
- 5 Giant-cell arteritis, temporal arteritis and polymyalgia rheumatica. A retrospective study of 63 patients. *Acta Medica Scandinavica*, **1977**, 201, 207-13 84
- 4 Treatment of hookworm anemia. *Scandinavian Journal of Infectious Diseases*, **1971**, 3, 65-9 1
- 3 Neutralizing antibodies directed against biologic agents to treat multiple sclerosis287-299
- 2 Intravenous immunoglobulin to treat multiple sclerosis444-453
- 1 Using Smartphones and Wearable Devices to Monitor Behavioral Changes During COVID-19 (Preprint) 4